Comments on: Medivation’s MDV3100 Demonstrates Substantial PSA Reductions In First Patient Groups Treated In Phase 1-2 Hormone Refractory Prostate Cancer Trial

Comments on: Medivation’s MDV3100 Demonstrates Substantial PSA Reductions In First Patient Groups Treated In Phase 1-2 Hormone Refractory Prostate Cancer Trial http://www.druginformations.org/medicine_news/2007/11/06/medivations-mdv3100-demonstrates-substantial-psa-reductions-in-first-patient-groups-treated-in-phase-1-2-hormone-refractory-prostate-cancer-trial/ Your best medicine news resource Sat, 11 Feb 2012 15:36:20 +0000 http://wordpress.org/?v=2.1.2